最后
罗氟司特
医学
临床试验
特应性皮炎
银屑病性关节炎
重症监护医学
药品
疾病
肺病
药理学
皮肤病科
内科学
作者
Letizia Crocetti,Giuseppe Floresta,Agostino Cilibrizzi,Maria Paola Giovannoni
出处
期刊:Molecules
[MDPI AG]
日期:2022-08-04
卷期号:27 (15): 4964-4964
被引量:34
标识
DOI:10.3390/molecules27154964
摘要
Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands for this target, along with the acquisition of precise information on biological requirements and linked therapeutic opportunities. The transition from pre-clinical to clinical phase was not easy for the majority of these compounds, mainly due to their significant side effects, and it took almost thirty years for a PDE4 inhibitor to become a drug i.e., Roflumilast, used in the clinics for the treatment of chronic obstructive pulmonary disease. Since then, three additional compounds have reached the market a few years later: Crisaborole for atopic dermatitis, Apremilast for psoriatic arthritis and Ibudilast for Krabbe disease. The aim of this review is to provide an overview of the compounds that have reached clinical trials in the last ten years, with a focus on those most recently developed for respiratory, skin and neurological disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI